Skip to main content
2026 Prospectus
Autoinflammatory Awareness Month 2026 executive healthcare observance hero.

· Executive Brief

Autoinflammatory Awareness Month 2026

A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 29 min read

Leadership signal

Autoinflammatory Awareness Month can serve as an executive operating checkpoint.

Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

Recurrent fever is a routing problem before it is a diagnosis

Autoinflammatory diseases are rare, varied and easy to miss. People often arrive through emergency departments, pediatric clinics and primary care with fevers, pain or rashes that come and go. Each visit may be handled well on its own while the pattern across visits goes unrecognized. The patient experiences a series of partial answers, and no single team is responsible for connecting them. For executives, the question is how long the route from first symptom to specialist diagnosis takes, and who owns it.

The answer, in published data, is often years. At a UK national referral center, the median diagnostic delay was 4.5 years for new diagnoses and 6 years for late-onset systemic autoinflammatory disease.[11] In a German registry of 152 patients treated with interleukin-1 targeted therapy, the delay between the first attack and that therapy was 17.8 years.[14] Inflammatory attacks had started before age 18 in 61.2% of those patients.[14]

Delay carries consequences that a health system can see. Longer diagnostic delay was associated with less favorable treatment outcomes in a 24-year cohort of adults with adult-onset Still’s disease.[1] In an international registry of familial Mediterranean fever, older age at diagnosis and longer disease duration were associated with higher risk of kidney complications.[10]

This brief adds evidence to the executive guidance above. It covers current evidence on delay and diagnosis, the pediatric-to-adult continuum, and access to genetic testing and targeted therapy. It then turns to equity and trust, the specialist and navigation workforce, and public communication. The goal is one accountable improvement in the route from recurrent symptoms to an owned specialist answer. Every figure in the sections below comes from a cited study; the operating suggestions are executive guidance and imply no clinical protocol. The focus throughout is on routes, owners and measures.

Current evidence

What the evidence shows about delay, diagnosis and uncertainty

Delay appears across disease types and age groups. In a pediatric center in Istanbul, the mean diagnostic delay for mevalonate kinase deficiency was 67.6 months among 33 patients.[9] It was longer for patients with an exon 10 MEFV mutation (95.0 months) and for those with a history of tonsillectomy (99.5 months).[9] The authors advised that patients with periodic fever suggestive of familial Mediterranean fever but atypical features be evaluated for mevalonate kinase deficiency, with further genetic testing.[9] Attacks in that cohort recurred at a median frequency of 12 per year, so each year of delay meant many unexplained episodes.[9]

Shorter routes are possible where care is concentrated. At the only pediatric tertiary hospital in Latvia, the median time from symptom onset to diagnosis of chronic nonbacterial osteomyelitis was 4.1 months.[2] The pooled incidence there was 0.31 per 100,000 children, and every patient received whole body MRI.[2] A single national referral point appears to make rare presentations easier to recognize and track. The comparison is indirect, but the contrast with multi-year delays elsewhere is a useful prompt for service design.

Many patients never receive a defined label. A review of undifferentiated systemic autoinflammatory disease reported that up to 73% of patients in some series have an autoinflammatory phenotype without an identified pathogenic variant or established diagnosis.[7] Diagnosis depends on repeated documentation of inflammation, symptoms over at least six months and exclusion of infection, cancer and other conditions.[7] That process requires continuity across many visits, which is exactly where fragmented systems lose patients.

Initial diagnoses also need revisiting. In a Japanese cohort of 504 patients clinically suspected of familial Mediterranean fever, 34 (6.7%) were ultimately diagnosed with a different disease one year after genetic testing.[15] The authors called for careful follow-up and reanalysis of the diagnosis for patients with atypical findings and no exon 10 variants.[15]

Autoinflammatory disease also carries risks beyond its own symptoms. In a population cohort of 9,736 adults with familial Mediterranean fever and 97,360 matched controls, the adjusted hazard ratio for psoriatic arthritis was 3.52.[8] Coordinated care across rheumatology, dermatology and nephrology is therefore part of the operating model, not an optional extra. Patients with familial Mediterranean fever made up the largest diagnostic group at the UK center, at 31% of those with systemic autoinflammatory disease.[11] Common diagnoses still need coordinated follow-up across specialties.

Figure 1

Years can pass between first symptoms and specialist care

Years can pass between first symptoms and specialist careReported diagnostic or treatment delay, in years, as defined in each study. Values are copied from the cited studies [11], [14]; none is estimated.0%25%50%75%100%Median diagnostic delay, patients whotransitioned from pediatric careMedian diagnostic delay, patients who transitioned from pediatric care: 2% (source [11])2%[11]Median diagnostic delay, new diagnosesMedian diagnostic delay, new diagnoses: 4.5% (source [11])4.5%[11]Median diagnostic delay, late-onsetdiseaseMedian diagnostic delay, late-onset disease: 6% (source [11])6%[11]Delay from first attack to interleukin-1targeted therapyDelay from first attack to interleukin-1 targeted therapy: 17.8% (source [14])17.8%[14]Source [11]Source [14]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Reported diagnostic or treatment delay, in years, as defined in each study. Values are copied from the cited studies [11], [14]; none is estimated.

Data note. The first three values share one center and definition, but the fourth comes from a different registry and measures delay to therapy rather than diagnosis, so the comparison across studies is indirect.

Limitation. Both sources are specialist referral populations, so patients never referred are not counted; delay in community settings may differ.

Figure data (4 rows)
Figure 1 data: Years can pass between first symptoms and specialist care
MeasureValuePopulation, setting and year as reportedSource
Median diagnostic delay, patients who transitioned from pediatric care2%UK national referral center, new patients seen in 2022[11]
Median diagnostic delay, new diagnoses4.5%UK national referral center, new patients seen in 2022[11]
Median diagnostic delay, late-onset disease6%UK national referral center, newly diagnosed late-adult-onset disease, 2022[11]
Delay from first attack to interleukin-1 targeted therapy17.8%152 patients in a German anti-IL-1 registry, 2013 to 2022; measures time to therapy, not to diagnosis[14]
A rheumatologist listens as a young man shares a symptom diary on his phone, his mother beside him.
Illustrative image. Median diagnostic delay at one national referral center ranged from 2 to 6 years by patient group.[11]

Continuum of care

From pediatric clinic to adult service without a gap

Many autoinflammatory diseases begin in childhood and continue for life, so transition is a predictable event. In a Spanish pediatric rheumatology unit that evaluated 925 patients over ten years, autoinflammatory diseases accounted for 10.2% of the case mix.[4] At the time of analysis, 45.3% of patients were still followed in pediatric care and 9% were in transition to adult consultations.[4] Those figures describe a steady pipeline that adult services can plan for. Adult rheumatology teams can estimate demand from pediatric panels a year or more in advance, if the two services share that information.

Adult centers see the result of that pipeline. At the UK national referral center, 21% of patients diagnosed with systemic autoinflammatory disease had transitioned from pediatric care.[11] Their median age at diagnosis was 7 years, and their median diagnostic delay was 2 years.[11] Patients who arrive through transition already carry a diagnosis, so the risk shifts from finding the disease to keeping treatment and monitoring continuous. Transfer summaries, medication histories and genetic results need to move with the patient rather than being rebuilt by the adult team. A joint visit, or a direct clinician-to-clinician handoff, helps the adult team understand the patient’s history and preferences.

Continuity also matters when treatment changes. In a cohort of 54 patients with familial Mediterranean fever who stopped colchicine without a clinical indication, outcomes differed by attack frequency in the prior six months.[6] Within one year, 23.5% of the attack-free group and 2.7% of the group with prior attacks remained attack-free with low inflammatory markers.[6] The authors stressed that close monitoring is a must after discontinuation.[6]

Long-term outcomes reinforce the case for planned follow-up. Among 598 patients in an international familial Mediterranean fever registry, 80 had proteinuria, 61 had amyloidosis and 25 had kidney failure.[10] In the German registry, 24 patients already had secondary AA amyloidosis when interleukin-1 targeted therapy began.[14] Their mean age was 16.4 years at the first attack and 44.9 years at amyloidosis diagnosis.[14]

For executives, the continuum question is simple to state. Every adolescent with an autoinflammatory diagnosis should have a named adult service that has accepted the referral before pediatric care ends, with monitoring that does not lapse in between. Transition readiness, first adult appointment and continuity of therapy are all measurable. Each needs an owner on both the pediatric and the adult side.

Figure 3

Why the pathway breaks

Cause-and-effect diagram: Patients with recurrent fevers and other autoinflammatory features wait years for a specialist diagnosis and continuous treatmentUnranked qualitative cause-and-effect diagram for the outcome in the box: Patients with recurrent fevers and other autoinflammatory features wait years for a specialist diagnosis and continuous treatment Causes are assembled from the cited literature [1], [5], [6], [7], [11], [12], [14], [15]; categories are not weighted and their order carries no meaning.Patients with recurrent feversand other autoinflammatoryfeatures wait years for aspecialist diagnosis andcontinuous treatmentPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Few clinicians with autoinflammatory disease expertise
  • No navigator tracking referrals, results and transition dates
  • Referring clinicians unfamiliar with recurring patterns

Process

  • Episodes treated one visit at a time without pattern review
  • No accepted adult service before pediatric care ends
  • Diagnoses not revisited when findings are atypical

Technology

  • Genetic testing hard to order or interpret
  • Episode history scattered across emergency and clinic records
  • No shared tracking of prior authorization status

Environment

  • Specialist care concentrated in a few referral centers
  • Travel and cost burdens for repeated visits
  • Low household income affecting adherence

Policy

  • Prior authorization delays for targeted therapy
  • Unclear referral criteria for recurrent fever
  • No funding for registry participation

Measurement

  • Time to diagnosis not measured
  • Adherence not assessed routinely
  • Adverse events not recorded consistently

Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients with recurrent fevers and other autoinflammatory features wait years for a specialist diagnosis and continuous treatment Causes are assembled from the cited literature [1], [5], [6], [7], [11], [12], [14], [15]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleFew clinicians with autoinflammatory disease expertise; No navigator tracking referrals, results and transition dates; Referring clinicians unfamiliar with recurring patterns
ProcessEpisodes treated one visit at a time without pattern review; No accepted adult service before pediatric care ends; Diagnoses not revisited when findings are atypical
TechnologyGenetic testing hard to order or interpret; Episode history scattered across emergency and clinic records; No shared tracking of prior authorization status
EnvironmentSpecialist care concentrated in a few referral centers; Travel and cost burdens for repeated visits; Low household income affecting adherence
PolicyPrior authorization delays for targeted therapy; Unclear referral criteria for recurrent fever; No funding for registry participation
MeasurementTime to diagnosis not measured; Adherence not assessed routinely; Adverse events not recorded consistently

Access

Access to genetic testing, specialist review and targeted therapy

Specialist clinics and genetic testing shape who receives a diagnosis. The UK center’s authors noted that specialist clinics and available genetic testing enable increased diagnosis of these disorders.[11] Of 306 new patients seen there in 2022, 121 (39.5%) were diagnosed with systemic autoinflammatory disease.[11] Among them, 59 (49%) had genetic results supportive of monogenic disease, using a sequencing panel of 24 related genes or single-gene testing.[11]

Genetic results support, but do not replace, clinical judgment. In the German registry, genetic analysis confirmed the diagnosis in 87.3% of patients with familial Mediterranean fever, 65.2% with cryopyrin-associated periodic syndromes and 94.8% with TNF receptor-associated periodic syndrome.[14] Variants of unknown significance were common, and patients with them were older at onset.[14] Access therefore means both ordering the test and having expertise to interpret and revisit it. Systems without in-house genetics can arrange formal agreements with a referral center so that results are reviewed by people who see these diseases often.

Targeted therapy access matters once a diagnosis is made. In an international registry of 158 patients with familial Mediterranean fever treated with canakinumab, complete clinical and laboratory response occurred in 45.6% at 3 months and 58.6% at 12 months.[3] Discontinuation for inefficacy was rare, at no more than 6%.[3] In the RELIANCE registry of 168 patients across four monogenic diseases, about 70% remained in remission under canakinumab treatment.[13]

Real-world cohorts also show that therapy pathways need flexibility. In a single-center cohort of 93 adults with adult-onset Still’s disease, response rates were similar for anakinra and tocilizumab (55.3% versus 58.3%).[1] Among 17 patients who did not respond to anakinra, 16 received tocilizumab and 11 achieved complete remission.[1] Formulary, prior authorization and specialty pharmacy processes determine whether such switches happen promptly.

Leaders should know how long it takes from a specialist’s decision to the first dose of a targeted therapy. They should also know which step, from benefits review to home infusion or injection teaching, most often stalls. Those intervals are rarely reported, yet they are within the organization’s control. A monthly review of delayed starts, with the pharmacy, benefits and clinic teams in the same room, can surface the most common failure point quickly.

Executive guidance · System route

Build one visible operating route for Autoinflammatory Awareness Month.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Coordinate the partner route
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Coordinate the partner route

    Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryCoordinate thepartner routeProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Coordinate the partner routeAlign internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Equity, adherence and the trust that sustains lifelong treatment

Lifelong treatment depends on daily choices that patients make outside the clinic. In a study of 104 adults with familial Mediterranean fever taking colchicine, adherence was low in 28.8%, moderate in 45.2% and high in 26.0%.[5] Younger age and low household income were associated with low adherence.[5] The authors recommended routine adherence assessment and targeted support for potentially vulnerable subgroups.[5]

Income-linked adherence gaps are an equity signal, not a patient failing. Medication costs, pharmacy access, work schedules and understanding of long-term risk all sit within the system’s reach. Pairing adherence screening with financial counseling and pharmacy outreach turns a finding into a service.

Ancestry and geography also shape presentation and risk. In the German registry, Turkish-Armenian ancestry correlated with MEFV variants and higher familial Mediterranean fever disease activity compared with German ancestry.[14] In the international kidney analysis, ethnicity and country of residence each accounted for a small share of variation in amyloidosis, with intraclass correlation coefficients of 6.7% and 6.8%.[10] Clinical risk factors such as older age at diagnosis and longer disease duration were identified independent of ethnicity or residence.[10] Faster diagnosis is therefore itself an equity lever, because the risk it reduces applies across groups.

That finding has a practical message for equity work. Communities with a high prevalence of familial Mediterranean fever need fast access, but so do patients from groups in which clinicians may not expect the disease. Referral criteria built on symptoms and inflammatory patterns, rather than ancestry alone, reduce the chance that a patient is overlooked. Interpreter access and translated materials matter for families whose first language differs from the clinic’s.

Trust also depends on how decisions about stopping treatment are handled. In the colchicine discontinuation cohort, the patients had stopped voluntarily rather than on clinical advice.[6] Some later restarted, and three patients in the group with prior attacks resumed colchicine within one year.[6] Open conversations about side effects, goals and monitoring can keep such decisions inside the care relationship rather than outside it. Leaders can support that by giving clinics enough visit time for shared decisions and a nurse contact families can reach between visits.

A phlebotomist labels sample tubes while the young man rests in the lab chair with a bandage on his arm.
Illustrative image. Nearly half of patients diagnosed at one specialist center had genetic results supportive of monogenic disease.[11]

Human infrastructure

Specialists, navigators and the registries that extend their reach

Rare disease expertise is scarce, so its reach depends on structure. The Latvian experience shows how one national pediatric tertiary hospital can identify and follow a rare bone disease across a whole country.[2] In that cohort, nonsteroidal anti-inflammatory drugs produced a complete response in only 15.4% of patients, and many needed escalation to second-line treatment.[2] Escalation decisions of that kind require specialist time and a reliable route back to the specialist. Without that route, patients may cycle through urgent care while waiting for a follow-up slot.

Navigation is the human link that makes such routes work. A nurse or coordinator who tracks referrals, genetic test results, prior authorizations and transition dates can prevent the gaps that lengthen delay. That role is especially valuable when a diagnosis remains undifferentiated and follow-up depends on repeated testing over at least six months.[7] Navigation can also coordinate genetic counseling, which helps families understand results that are uncertain or that may affect relatives.

Registries extend the workforce by turning individual cases into shared learning. The Eurofever registry held complete safety information for 2,464 patients, with 479 adverse events reported in 275 patients.[12] Of these events, 82 were serious and 99 were judged drug-related by physicians.[12] The authors emphasized the importance of longitudinal and consistent recording of adverse events in rare conditions.[12]

Registries also show what routine care achieves. RELIANCE enrolled patients receiving canakinumab as part of routine care and assessed safety and disease activity every 6 months.[13] Of its 168 patients, 72 (43.1%) were children, so the registry spans pediatric and adult care.[13] Contributing data requires coordinator time, data agreements and clinician engagement, all of which need funding. The most frequently reported drug-related events involved biologic therapies (40 of 99 reports) and colchicine (31 of 99).[12] Shared data of that kind informs local safety monitoring as well.

Executives can treat registry participation as part of the specialist service. It supports benchmarking, safety surveillance and the case for staffing that a single center could not build alone. Participation also gives clinicians access to peers who have seen rare presentations, which shortens the learning curve for difficult cases. Leaders should name an owner for registry work so that it survives staff turnover.

Executive guidance · Operating dashboard

Use a small dashboard to expose friction and ownership.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilityPartner-route reliabilityImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Partner-route reliability

Do participating teams share one current route and understand who owns each dependency?

Candidate local measure
Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsPartner-route reliabilityOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Partner-route reliabilitySending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Close the loop across teams, settings, and partners.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. Name the sending and receiving owners, shared information, current status, and unresolved dependency.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Give leaders one view of route reliability and improvement.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signalExecutive questionCandidate ownerSuggested review point
Entry-point clarityCan people and staff identify the approved first step without searching across conflicting instructions?Executive sponsor and operational leadAt campaign launch and close
Ownership reliabilityDoes a specific team accept each request and make its status visible?Operational owner and participating teamsAt a locally defined cadence
Partner-route reliabilityDo participating teams share one current route and understand who owns each dependency?Sending and receiving ownersAt a locally defined cadence
Improvement closureDoes the organization correct recurring friction and report what changed?Improvement owner and executive sponsorUntil action is verified

Figure 5

Control points for the autoinflammatory disease route

Figure 5: Control points for the autoinflammatory disease route
Control pointRisk if missingOwnerEvidence of control
Recurrent fever referral criteriaRepeated episodes are treated singly and never referredChief medical officer with rheumatology leadPublished criteria and referral volume reviewed quarterly
Owned specialist referral queueReferrals wait without acknowledgmentRheumatology service managerTime from referral to specialist review reported monthly
Genetic testing and reanalysis pathwayResults are misread or never revisitedGenetics and rheumatology leadsDocumented interpretation and scheduled review for atypical cases
Accepted adult service before transitionAdolescents lose monitoring at transferPediatric and adult rheumatology leadsShare of transitioning patients with an accepted adult appointment
Targeted therapy access trackingPrior authorization or pharmacy steps stall treatmentSpecialty pharmacy leadDays from treatment decision to first dose
Routine adherence assessmentLow adherence goes unseen, especially among vulnerable groupsClinic nurse leadAdherence assessed at each visit and stratified by age and income
Registry and adverse event recordingSafety signals and outcomes are lostResearch and quality leadRegistry submissions and adverse event completeness audited

Control points derived from the cited evidence [3], [4], [5], [11], [12], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Clear signals for patients, families and referring clinicians

Public messaging for this month should help people recognize a pattern rather than self-diagnose. The useful message is that recurring fevers, rashes or pain with no clear cause deserve a coordinated look, and that the health system has a route for it. Messages should name the first step and the team that answers. They should avoid suggesting that awareness alone produces a diagnosis.

Referring clinicians need a different message. The evidence on delay suggests that the key signal is repetition: inflammatory episodes that return over months or years.[7] A short referral guide, built with rheumatology and genetics, can tell primary and emergency clinicians what to document and whom to call. It should also say how to revisit a diagnosis when the picture changes, as the Japanese cohort recommended.[15] The guide should be short enough to use during a busy shift and reviewed each year by the specialists who receive the referrals.

Communication about treatment should be honest about both benefit and uncertainty. In the canakinumab registry, complete response was 55.2% at last follow-up after a mean treatment duration of 45 months.[3] Delayed achievement of complete response was not uncommon, according to the authors.[3] Families who understand that response may take time are better prepared to stay in follow-up. Clinicians should explain what will be measured, how often, and who to call if symptoms return between visits. Written summaries in plain language help families share that plan with schools, employers and other clinicians.

Adherence conversations deserve the same care. In the colchicine adherence study, scores on the adherence scale correlated with both physician-rated and patient-rated adherence (r = 0.53 and 0.50).[5] A brief, routine question about missed doses is therefore a practical communication tool, not an accusation. Pharmacy refill data, where available, can add an objective view without placing the burden on the patient.

Finally, leaders should report what changes. A public statement that the organization measured time from referral to specialist review, and improved it, builds more trust than awareness messaging alone. Results should be shared with patient groups and referring clinicians who helped shape the route. Patient organizations can also help test whether public materials are clear, accurate and free of jargon before release.

A young man shoots hoops with a friend at a neighborhood basketball court in soft summer sun.
Illustrative image. In one pediatric rheumatology unit, 9% of patients were in transition to adult consultations at the time of analysis.[4]

Executive guidance · 90-day plan

Turn the observance into one sustained operating change.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how Autoinflammatory Awareness Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how Autoinflammatory Awareness Month communicationsconnect to real entry points, owners, transitions, andescalation.Days 1–30: Map how Autoinflammatory Awareness Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Test one internal or partner handoff and correct a verifiedcommunication, dependency, or ownership gap.Days 31–60: Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how Autoinflammatory Awareness Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testTest one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Make Autoinflammatory Awareness Month a starting point, not an endpoint.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Make ownership visible, test the route, and report what improved.

Executive action kit · Month observance

Turn Autoinflammatory Awareness Month into accountable action.

A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Take it with you

Filed under

Public Health and PreventionMonth

Leadership focus

Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.

Five-minute briefing

Inspect the operating sequence

Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Coordinate the partner route
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Public Health and Community Partners
Staff communication template

During Autoinflammatory Awareness Month, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

Autoinflammatory Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Treatment outcomes and predictors of macrophage activation syndrome in adult-onset Still’s disease: a 24 year single-centre experience. Scandinavian Journal of Rheumatology. 2026:1-9. https://doi.org/10.1080/03009742.2026.2656045
  2. 2. Chronic Nonbacterial Osteomyelitis in Latvia from 2014 to 2025: Case Series. Medicina. 2026;62(9):1642. https://doi.org/10.3390/medicina62091642
  3. 3. Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network. Rheumatology. 2026;65(8):keag361. https://doi.org/10.1093/rheumatology/keag361
  4. 4. Rheumatic diseases in childhood: Clinical and immunological characteristics of a pediatric cohort at a tertiary hospital. Reumatología Clínica (English Edition). 2026;22(3):502076. https://doi.org/10.1016/j.reumae.2026.502076
  5. 5. Sociodemographic and Clinical Determinants of Colchicine Adherence in Adults with Familial Mediterranean Fever: A Cross-Sectional Study. Rheumatology and Therapy. 2026;13(5):1357-1377. https://doi.org/10.1007/s40744-026-00883-w
  6. 6. Colchicine discontinuation in familial Mediterranean fever: short-term outcomes by pre-discontinuation attack frequency. Clinical Rheumatology. 2026;45(2):1257-1265. https://doi.org/10.1007/s10067-025-07874-2
  7. 7. Qu’est-ce qu’une maladie auto-inflammatoire indifférenciée chez un adulte ?. La Revue de Médecine Interne. 2026;47(6):317-324. https://doi.org/10.1016/j.revmed.2025.11.003
  8. 8. Increased risk of psoriatic arthritis in patients with familial Mediterranean fever: a population-based cohort study. Rheumatology. 2025;65(2):keaf607. https://doi.org/10.1093/rheumatology/keaf607
  9. 9. Mevalonate kinase deficiency in a familial Mediterranean fever endemic region: a single-center experience. The Turkish Journal of Pediatrics. 2025;67(4):483-492. https://doi.org/10.24953/turkjpediatr.2025.6015
  10. 10. Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry. Rheumatology. 2025;64(8):4776-4787. https://doi.org/10.1093/rheumatology/keaf181
  11. 11. Systemic autoinflammatory disease diagnoses in a single year from a UK national referral centre. Rheumatology. 2025;64(7):4218-4226. https://doi.org/10.1093/rheumatology/keaf165
  12. 12. Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry. Journal of Clinical Immunology. 2024;44(5):119. https://doi.org/10.1007/s10875-024-01719-4
  13. 13. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry. RMD Open. 2024;10(1):e003890. https://doi.org/10.1136/rmdopen-2023-003890
  14. 14. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry. Rheumatology International. 2023;44(2):263-271. https://doi.org/10.1007/s00296-023-05443-x
  15. 15. Variables for differential diagnosis of familial Mediterranean fever: Multiple correspondence analysis of a large Japanese cohort. Modern Rheumatology. 2023;34(4):784-790. https://doi.org/10.1093/mr/road084

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Diagnostic delay by patient group at a national referral center[11]2025Current evidenceSingle UK center, new patients in one year (2022); referral population may not reflect community case mix.
Delay from first attack to interleukin-1 targeted therapy and genetic confirmation[14]2023Current evidenceRetrospective German registry limited to patients who received anti-IL-1 therapy.
Diagnostic delay in mevalonate kinase deficiency[9]2025Current evidenceSingle pediatric center in a region where familial Mediterranean fever is endemic; 33 patients.
Time to diagnosis and treatment response in chronic nonbacterial osteomyelitis[2]2026Current evidenceCase series of 13 patients at one national pediatric hospital.
Undifferentiated systemic autoinflammatory disease[7]2026Current evidenceNarrative review; the 73% figure reflects some series only.
Revised diagnoses after genetic testing for suspected familial Mediterranean fever[15]2023Current evidenceJapanese cohort aged 13 and older; findings may differ in high-prevalence regions.
Psoriatic arthritis risk in familial Mediterranean fever[8]2025Current evidenceRetrospective database cohort in one health care provider; association only.
Pediatric case mix and transition status[4]2026Continuum of careSingle Spanish tertiary unit; descriptive data.
Outcomes after voluntary colchicine discontinuation[6]2026Continuum of careRetrospective single-center cohort of 54 patients with one-year follow-up.
Predictors of kidney complications and role of ethnicity and residence[10]2025Continuum of careRegistry data from referral centers; observational associations.
Real-world response to targeted therapy[1] [3] [13]2026, 2024AccessRegistry and single-center observational data without control groups; interim registry analysis.
Colchicine adherence and its sociodemographic determinants[5]2026Equity and trustCross-sectional study of 104 adults using a self-reported scale.
Adverse event monitoring in an international registry[12]2024Human infrastructurePhysician-reported events, partly retrospective; causality not assessed for all events.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.